Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...
Trevi Therapeutics, Inc. (NASDAQ:TRVI) reported topline results from its Phase 2a RIVER trial of Haduvio (oral nalbuphine ER) ...
Zacks Investment Research on MSN3d
TRVI Stock Soars on Meeting Primary Goal in Chronic Cough StudyShares of Trevi Therapeutics TRVI surged 41% yesterday after it reported positive top-line data from the phase IIa RIVER ...
Trevi Therapeutics (Nasdaq: TRVI) reported promising results from a mid-stage study of its experimental chronic cough ...
Clinical Trials Arena on MSN3d
Trevi’s Phase IIb chronic cough success spikes stock by 71%The company’s trial of Haduvio met its primary and secondary endpoints in reducing coughing fits across patients by 53%.
Trevi Therapeutics (TRVI) announced topline results from its Phase 2a RIVER trial of Haduvio for the treatment of patients with RCC. Haduvio ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...
The New Haven, Conn., biopharmaceutical company shared positive topline results from a Phase 2a trial of Haduvio for the treatment of patients with refractory chronic cough. Haduvio met the primary ...
Enrollment is now complete in the CORAL clinical trial of nalbuphine ER, to be marketed as Haduvio, for IPF patients with ...
Feb. 25, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER ...
New Haven, Connecticut Tuesday, March 11, 2025, 18:00 Hrs [IST] ...
Haduvio met the primary endpoint with a statistically-significant reduction (p<0.0001) in 24-hour cough frequency with a 57% placebo-adjusted change from baseline Haduvio showed similar efficacy ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback